Elsiglutide in the primary prevention of chemotherapy (CT)-induced diarrhea in patients with colorectal cancer (CRC) receiving 5-fluorouracil (5-FU)-based CT: A multinational, randomized, double-blind, placebo-controlled study.

Authors

Meinolf Karthaus

Hematology and Onkology, Klinikum Neuperlach, Munich, Germany

Meinolf Karthaus , Mikhail Fedyanin , Igor Bondarenko , Salvatore Chessari , Riccardo Spezia , Ruben Giorgino

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).

First Author: Tamas Pinter

insert_chart_outlined

Poster

2013 Gastrointestinal Cancers Symposium

bookmark_border

Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).

First Author: Tamas Pinter

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780).

First Author: Axel Grothey

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

Improved early prediction of individual prognosis for patients with mCRC: Joint modeling of tumor shrinkage with volume data for PFS and OS.

First Author: Ulrich Robert Mansmann